Abstract Library

#4089 Peptide receptor radionuclide therapy is effective for hormonal control of carcinoid syndrome

Introduction: Carcinoid syndrome (CS) is the most common functioning syndrome in neuroendocrine tumors (NET) and manifests in symptoms of flushing, diarrhea and fibrosis. Serotonin, a tryptophan metabolite, is considered the principal hormonal mediator of CS. Peptide receptor radionuclide therapy (PRRT) has established antiproliferative effects in NET, but the clinical and biochemical response to PRRT in CS patients is unknown.

Conference:

Presenting Author: Maas C

Authors: Maas C, Mulders M, Mirzaian M, van den Berg S, Brabander T,

Keywords: carcinoid syndrome, neuroendocrine tumor, peptide receptor radionuclide therapy, serotonin,

#3820 Metabolites in the tryptophan pathway as a diagnostic tool in neuroendocrine tumor patients

Introduction: A good and accessible biomarker is of great value in neuroendocrine tumor (NET) patients, especially considering its frequently indolent nature and long-term follow up.

Conference:

Presenting Author:

Authors: Johansen S, Hansen T, Meyer R, Jensen E, Goll R,

Keywords: serotonin, tryptophan pathway, LC-MS/MS, NEUROENDOCRINE TUMOR,

#3793 Decellularised pancreas explants as a novel 3D model for pancreatic neuroendocrine tumors (PNETs) biomarker discovery

Introduction: The lack of preclinical models of pancreatic neuroendocrine tumors (pNETs) challenges advancement in biomarker discovery. Culturing cancer cells in their native tissue enables the study of complex tumor cell-ECM interactions, products of which could be utilised as disease biomarkers.

Conference:

Presenting Author: Ney A

Authors: Ney A, Al-Akkad W, Sedlak E, Garcia-Sampedro A, Hall A,

Keywords: Disease model, Tumor microenvironment, Biomarker discovery, Pancreatic NET,